Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply-established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management.
• Milan based Epsilen Bio is acquired by Chroma Medicine, which launches today with $125M in financing • Epsilen Bio, now a wholly owned subsidiary of Chroma Medicine, will continue to conduct groundbreaking epigenetic editing R&D in Milan in collaboration...
The fund will invest in companies leveraging biotechnology to develop sustainable solutions Sofinnova Industrial Biotech II is part of the VC firm’s pioneering strategy initiated over a decade ago PARIS, France – November 17, 2021 - Sofinnova Partners, a leadi...
Horizons Ventures and Sofinnova Partners Co-Lead Investment in Market-leading Life Sciences Software Company That Transforms the Way Scientists Automate Experimentation and Share Insights November 16, 2021 04:30 AM Eastern Standard Time
November 09, 2021 03:00 AM Eastern Standard Time PARIS--(BUSINESS WIRE)--Home Biosciences, Europe’s first venture builder fully dedicated to biotech, announced today a $15 million Seed financing led by Redmile Group and Sofinnova Partners.
SCHLIEREN, Switzerland--(BUSINESS WIRE)--Nov 5, 2021-- GlycoEra AG announced today the close of a CHF 45 million ($49 million) Series A financing round, co-led by renowned US and European life science investors, 5AM Ventures, Roche Venture Fund and Sofinnova P...